The SELECT trial demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its ...

Hyderabad: Dr. Reddy's Laboratories is gearing up to shake up the global weight-loss drug market with the launch of an ...

After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic versions of Novo Nordisk’s lucrative semaglutide drugs for diabetes and obesi | ...

Weight loss injections could be key to controlling a chronic condition in thousands of Brits, new research suggests ...

According to a Phase 3 trial published in The Lancet Diabetes & Endocrinology, a once-weekly combination of semaglutide and ...

Ongoing patent battle between Novo Nordisk and Dr Reddy’s Laboratories over semaglutide export to multiple countries.

Researchers said the drugs should be explored as a potential treatment for obese people with the respiratory condition, who ...

What happens when you stop taking Ozempic®? There’s no one-size-fits-all answer to this question. When you stop taking ...

GLP-1 drugs may reduce asthma symptoms in obese adults, offering a steroid-free alternative to treatment. The study includes ...

The Patented Medicine Prices Review Board’s mandate is to make sure that drug prices are not excessive. However, new ...

Longer treatment duration, not having diabetes, and using semaglutide are among the factors linked to better weight reduction over 12 months.

(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...